Dupixent®（Dupilumab）已在歐盟獲批，成爲首個針對慢性阻塞性肺病患者的靶向

快訊 · 07/03 13:00

Dupixent® (Dupilumab) Approved in the European Union as the First-Ever Targeted Therapy for Patients With Copd

Dupixent®（Dupilumab）已在歐盟獲批，成爲首個針對慢性阻塞性肺病患者的靶向治療。